DAX24.958 +2,3%Est506.025 +2,7%MSCI World4.343 -0,1%Top 10 Crypto10,47 +0,7%Nas25.326 +1,0%Bitcoin70.039 +1,4%Euro1,1761 +0,6%Öl101,5 -8,0%Gold4.677 +2,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Infineon 623100 Rheinmetall 703000 SAP 716460 NVIDIA 918422 AMD (Advanced Micro Devices) 863186 NEL ASA A0B733 Novo Nordisk A3EU6F Siemens Energy ENER6Y Lufthansa 823212 Intel 855681 Amazon 906866 BioNTech (ADRs) A2PSR2 Commerzbank CBK100 Allianz 840400 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX knackt 25.000er-Marke -- HENSOLDT: Milliarden-Orderbuch sprengt Analysten-Erwartungen -- Ölaktien, Disney, Uber, BMW, RENK, Novo Nordisk, Infineon, VW, AMD und weitere Chipaktien im Fokus
Top News
Ausblick: Rheinmetall mit Zahlen zum abgelaufenen Quartal Ausblick: Rheinmetall mit Zahlen zum abgelaufenen Quartal
Heidelberg Materials-Aktie tendiert nach oben: Prognose für 2026 trotz Umsatzminus bestätigt Heidelberg Materials-Aktie tendiert nach oben: Prognose für 2026 trotz Umsatzminus bestätigt
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
175,45 EUR -0,95 EUR -0,54 %
STU
205,75 USD -2,49 USD -1,20 %
vorbörslich
BTT
finanzen.net zero
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.313,80 Mrd. EUR

KGV96,78Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
PR NewswireRINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
PR NewswireRefer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
PR NewswireAbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireAbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR NewswireAbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
PR NewswireAbbVie Completes Acquisition of Landos Biopharma
PR NewswireAbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
PR NewswireAbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PR NewswireQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
PR NewswireQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
PR NewswireAbbVie to Present at the Bank of America Securities Healthcare Conference
PR NewswireAbbVie Reports First-Quarter 2024 Financial Results
PR NewswireNew Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
PR NewswirePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
PR NewswireAbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
PR NewswireSkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
PR NewswireAbbVie to Host First-Quarter 2024 Earnings Conference Call
PR NewswireAllergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
PR NewswireAllergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
PR NewswireAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
PR NewswireU.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
PR NewswireALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
PR NewswireAbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
PR NewswireAbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
PR NewswireJUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
PR NewswireDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
PR NewswireDragonfly hat nach der Verabreichung des ersten Patienten in der klinischen Phase-1-Studie von AbbVie zur Bewertung von DF4101/ABBV-303 eine Meilensteinzahlung erhalten
PR NewswireDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
PR NewswireDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
PR NewswireAbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
PR NewswireAbbVie to Present at the TD Cowen 44th Annual Health Care Conference
PR NewswireU.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
PR NewswireAbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
PR NewswireAbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
PR NewswireAbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Completes Acquisition of ImmunoGen
PR NewswireAbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada
PR NewswireCalibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.